MedTrace Logo

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.

NCT05773586 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2026-04-15

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of APG-5918 in Healthy Subjects or Anemic Patients.

Conditions

Interventions

DRUG

Placebo

Matching placebo

DRUG

APG-5918

oral tablets 10mg, 50mg, 200mg.

Sponsors & Collaborators

  • Ascentage Pharma Group Inc.

    lead INDUSTRY

Principal Investigators

  • Zhongyuan Xu, M.D.,Ph.D. · Nanfang Hospital, Southern Medical University

  • Yang Liang, M.D.,Ph.D. · Sun Yat-Sen University Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-13
Primary Completion
2027-12-31
Completion
2028-07-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05773586 on ClinicalTrials.gov